NCT06768489

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	JNJ-79635322	JNJ-79635322 will be administered subcutaneously.
DRUG	Daratumumab	Daratumumab will be administered subcutaneously.
DRUG	Pomalidomide	Pomalidomide will be administered orally.
DRUG	Lenalidomide	Lenalidomide will be administered orally.

Timeline

• Start date: 2024-12-04
• Primary completion: 2027-11-19
• Completion: 2028-11-23
• First posted: 2025-01-10
• Last updated: 2026-04-13

Locations

14 sites across 4 countries: Australia, Israel, Netherlands, Spain

Regulatory

• FDA-regulated drug study